Category: Chronic Pulmonary Disorders

Chronic Pulmonary Disorders

Fifth Annual World Bronchiectasis Day Set for July 1

Global organizations unite to raise awareness and improve care for more than 1 million people living with bronchiectasis.

Chronic Pulmonary Disorders

CFTR Modulator Use Linked to Lower Anxiety in Children and Parents

New research suggests cystic fibrosis transmembrane conductance regulator (CFTR) modulators may provide mental health benefits for pediatric patients and their caregivers early in treatment.

Chronic Pulmonary Disorders

Hydroxyurea Reduced Mortality for Children With Sickle Cell Anemia

A 10-year study in sub-Saharan Africa revealed that a higher dose of the oral medication Hydroxyurea improved survival and growth outcomes in children with sickle cell anemia.

Asthma

Tezepelumab Reduced Asthma Attacks

A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.

COPD

Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function

AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.

Cystic fibrosis

COVID-19 Outcomes in Cystic Fibrosis Transplant Patients

New research indicates that baseline lung health is a stronger predictor of SARS-CoV-2 outcomes in cystic fibrosis transplantation patients than the time elapsed since transplantation.

Pulmonary Fibrosis

Nebulized Treprostinil Preserved IPF Lung Function

Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).

Allergies

Fatal Pediatric Anaphylaxis Linked to Delays in Epinephrine Treatment

New studies suggest that airway and breathing failures are the primary causes of death in childhood food anaphylaxis, requiring a shift in emergency management protocols.

Other Chronic Diseases

Inhaled Molgramostim Improved Exercise Capacity

Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.